SECOND REGULAR SESSION
HOUSE BILL NO. 2267
102ND GENERAL ASSEMBLY
INTRODUCED BY REPRESENTATIVE PETERS.
4887H.01I DANARADEMANMILLER,ChiefClerk
AN ACT
To amend chapter 376, RSMo, by adding thereto three new sections relating to insurance
coverage of pharmacy services, with penalty provisions.
Be it enacted by the General Assembly of the state of Missouri, as follows:
Section A. Chapter 376, RSMo, is amended by adding thereto three new sections, to
2 be known as sections 376.411, 376.414, and 376.415, to read as follows:
376.411. 1. For purposes of this section, the following terms mean:
2 (1) "Clinician-administered drug", any legend drug, as defined in section
3 338.330, that is administered by a health care provider who is authorized to administer
4 the drug;
5 (2) "Health carrier", the same meaning given to the term in section 376.1350;
6 (3) "Participating provider", the same meaning given to the term in section
7 376.1350;
8 (4) "Pharmacybenefitsmanager",thesamemeaninggiventotheterminsection
9 376.388.
10 2. A health carrier, a pharmacybenefits manager,or an agent oraffiliate ofsuch
11 health carrier or pharmacy benefits manager shall not:
12 (1) Impose any penalty, impediment, differentiation, or limitation on a
13 participating provider for providing medically necessary clinician-administered drugs
14 regardless of whether the participating provider obtains such drugs from a provider
15 that is in the network including, but not limited to, refusing to approve or pay or
16 reimbursing less than the contracted payment amount;
EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is
intended to be omitted from the law. Matter in bold-face type in the above bill is proposed language.
HB 2267 2
17 (2) Impose any penalty, impediment, differentiation, or limitation on a covered
18 personwhoisadministeredmedicallynecessaryclinician-administereddrugsregardless
19 of whether the participating provider obtains such drugs from a provider that is in the
20 network including, but not limited to, limiting coverage or benefits; requiring an
21 additional fee, higher co-payment, or higher coinsurance amount; or interfering with a
22 patient's ability to obtain a clinician-administered drug from the patient's provider or
23 pharmacy of choice by any means including, but not limited to, inducing, steering, or
24 offering financial or other incentives; or
25 (3) Impose any penalty, impediment, differentiation, or limitation on any
26 pharmacy, including any class B hospital pharmacy as defined in section 338.220, that is
27 dispensing medically necessary clinician-administered drugs regardless of whether the
28 participating provider obtains such drugs from a provider that is in the network
29 including, but not limited to, requiring a pharmacy to dispense such drugs to a patient
30 with the intention that the patient will transport the medication to a health care
31 provider for administration.
32 3. Theprovisionsofthissectionshallnotapplyiftheclinician-administereddrug
33 is not otherwise covered by the health carrier or pharmacy benefits manager.
376.414. 1. For purposes of this section, the following terms mean:
2 (1) "340B drug", a drug that is:
3 (a) A covered outpatient drug as defined in Section 340B of the Public Health
4 Service Act, 42 U.S.C. Section 256b, enacted by Section 602 of the Veterans Health Care
5 Act of 1992, Pub. L. 102-585; and
6 (b) Purchased under an agreement entered into under 42 U.S.C. Section 256b;
7 (2) "Covered entity", the same meaning given to the term in Section 340B(a)(4)
8 of the Public Health Service Act, 42 U.S.C. Section 256b(a)(4);
9 (3) "Health carrier", the same meaning given to the term in section 376.1350;
10 (4) "Pharmacy", an entity licensed under chapter 338;
11 (5) "Pharmacybenefitsmanager",thesamemeaninggiventotheterminsection
12 376.388.
13 2. A health carrier, a pharmacybenefits manager,or an agent oraffiliate ofsuch
14 health carrier or pharmacy benefits manager shall not discriminate against a covered
15 entity or a pharmacy including, but not limited to, by doing any of the following:
16 (1) Reimbursing a covered entity or pharmacy for a quantity of a 340B drug in
17 an amount less than it would pay to any other similarly situated pharmacy that is not a
18 covered entity or a pharmacy for such quantity of such drug on the basis that the entity
19 or pharmacy is a covered entity or pharmacy or that the entity or pharmacy dispenses
20 340B drugs;
HB 2267 3
21 (2) Imposing any terms or conditions on covered entities or pharmacies that
22 differ from such terms or conditions applied to other similarly situated pharmacies or
23 entitiesthatarenotcoveredentitiesonthebasisthattheentityorpharmacyisacovered
24 entity or pharmacy or that the entity or pharmacy dispenses 340B drugs including, but
25 not limited to, terms or conditions with respect to any of the following:
26 (a) Fees, chargebacks, clawbacks, adjustments, or other assessments;
27 (b) Professional dispensing fees;
28 (c) Restrictions or requirements regarding participation in standard or
29 preferred pharmacy networks;
30 (d) Requirements relating to the frequency or scope of audits or to inventory
31 management systems using generally accepted accounting principles; and
32 (e) Any other restrictions, conditions, practices, or policies that, as specified by
33 thedirectorofthedepartmentofcommerceandinsurance,interferewiththeabilityofa
34 covered entity to maximize the value of discounts provided under 42 U.S.C. Section
35 256b;
36 (3) Interfering with an individual's choiceto receive a 340B drug from a covered
37 entity or pharmacy, whether in person or via direct delivery, mail, or other form of
38 shipment, by any means including, but not limited to, modifying a patient's payment
39 limitations or cost-sharing obligations on the basis of participation, in whole or in part,
40 in the 340B drug pricing program;
41 (4) Discriminating in reimbursement to a covered entity or pharmacy based on
42 the determination or indication a drug is a 340B drug;
43 (5) Requiring a covered entity or pharmacy to identify, either directly or
44 through a third party, a 340B drug sooner than forty-five days after the point of sale of
45 the 340B drug;
46 (6) Refusing to contract with a covered entity or pharmacy for reasons other
47 than those that apply equally to entities that are not covered entities or similarly
48 situated pharmacies, or on the basis that:
49 (a) The entity is a covered entity; or
50 (b) Theentityorpharmacyisdescribedinanyofsubparagraphs(A)to(O)of42
51 U.S.C. Section 235b(a)(4);
52 (7) Denying the covered entity the ability to purchase drugs at 340B program
53 pricing by substituting a rebate discount;
54 (8) Refusing to cover drugs purchased under the 340B drug pricing program; or
55 (9) Requiring a covered entity or pharmacy to reverse, resubmit, or clarify a
56 340B drug pricing claim after the initial adjudication unless these actions are in the
HB 2267 4
57 normal course of pharmacy business and not related to 340B drug pricing, except as
58 required by federal law.
59 3. A pharmaceutical manufacturer or an agent or affiliate of such manufacturer
60 shall not deny, restrict, prohibit, or otherwise discriminate against, either directly or
61 indirectly, the acquisition by or delivery of a 340B drug to a pharmacy that is under
62 contract with a covered entity to receive and dispense 340B drugs on behalf of the
63 covered entity. Any violation of this subsection shall be an unlawful practice within the
64 meaning of section 407.020, and any action authorized in sections 407.010 to 407.130
65 may be taken.
66 4. The director of the department of commerce and insurance shall impose a
67 civil penalty on any health carrier, pharmacy benefits manager, or agent or affiliate of
68 such health carrier or pharmacy benefits manager that violates the requirements of this
69 section. Such penalty shall not exceed five thousand dollars per violation per day.
70 5. The director of the department of commerce and insurance shall promulgate
71 rules to implement the provisions of this section. Any rule or portion of a rule, as that
72 term is defined in section 536.010, that is created under the authority delegated in this
73 section shall become effective only if it complies with and is subject to all of the
74 provisions of chapter 536 and, if applicable, section 536.028. This section and chapter
75 536 are nonseverable and if any of the powers vested with the general assembly
76 pursuanttochapter536toreview,todelaytheeffectivedate,ortodisapproveandannul
77 a rule are subsequently held unconstitutional, then the grant of rulemaking authority
78 and any rule proposed or adopted after August 28, 2024, shall be invalid and void.
376.415. 1. For purposes of this section, the following terms mean:
2 (1) "Biological product", the same meaning given to the term in 42 U.S.C.
3 Section 262(i);
4 (2) "Biosimilar",thesamemeaninggiventothetermin42U.S.C.Section262(i);
5 (3) "Health carrier", the same meaning given to the term in section 376.1350;
6 (4) "Pharmacybenefitsmanager",thesamemeaninggiventotheterminsection
7 376.388;
8 (5) "Reference product", the same meaning given to the term in 42 U.S.C.
9 Section 262(i).
10 2. A health carrier, a pharmacybenefits manager,or an agent oraffiliate ofsuch
11 health carrier or pharmacy benefits manager that provides coverage for a reference
12 product or a biological product that is biosimilar to the reference product shall provide
13 coverage for the reference product and all biological products that have been deemed
14 biosimilar to the reference product. The scope, extent, and amount of such required
HB 2267 5
15 coverageshallbethesameincluding,butnotlimitedto,anypaymentlimitationsorcost-
16 sharing obligations.
✔